These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20504240)

  • 1. Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.
    Park WB; Choe PG; Song KH; Jeon JH; Park SW; Kim HB; Kim NJ; Oh MD; Choe KW
    Clin Infect Dis; 2010 Jul; 51(1):101-6. PubMed ID: 20504240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
    Rodríguez-Nóvoa S; Martín-Carbonero L; Barreiro P; González-Pardo G; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS; 2007 Jan; 21(1):41-6. PubMed ID: 17148966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.
    Choe PG; Park WB; Song JS; Kim NH; Song KH; Park SW; Kim HB; Kim NJ; Oh MD
    J Korean Med Sci; 2010 Oct; 25(10):1427-30. PubMed ID: 20890421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.
    Culley CL; Kiang TK; Gilchrist SE; Ensom MH
    Ann Pharmacother; 2013 Apr; 47(4):561-72. PubMed ID: 23548653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil.
    Turatti L; Sprinz E; Lazzaretti RK; Kuhmmer R; Agnes G; Silveira JM; Basso RP; Pinheiro CA; Silveira MF; de Almeida S; Ribeiro JP; Mattevi VS
    AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1015-8. PubMed ID: 22050734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.
    Ferraris L; Viganò O; Peri A; Tarkowski M; Milani G; Bonora S; Adorni F; Gervasoni C; Clementi E; Di Perri G; Galli M; Riva A
    J Antimicrob Chemother; 2012 Sep; 67(9):2236-42. PubMed ID: 22661571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.
    Lankisch TO; Moebius U; Wehmeier M; Behrens G; Manns MP; Schmidt RE; Strassburg CP
    Hepatology; 2006 Nov; 44(5):1324-32. PubMed ID: 17058217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
    Rodríguez Nóvoa S; Barreiro P; Rendón A; Barrios A; Corral A; Jiménez-Nacher I; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Jan; 42(2):291-5. PubMed ID: 16355344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
    Ma Q; Brazeau D; Zingman BS; Reichman RC; Fischl MA; Gripshover BM; Venuto CS; Slish JC; DiFrancesco R; Forrest A; Morse GD
    Pharmacogenomics; 2007 Mar; 8(3):227-35. PubMed ID: 17324111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.
    Panagopoulos P; Paraskevis D; Katsarolis I; Sypsa V; Detsika M; Protopapas K; Antoniadou A; Papadopoulos A; Petrikkos G; Hatzakis A
    Int J STD AIDS; 2014 Oct; 25(12):860-5. PubMed ID: 24516079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir.
    Boyd MA; Srasuebkul P; Ruxrungtham K; Mackenzie PI; Uchaipichat V; Stek M; Lange JM; Phanuphak P; Cooper DA; Udomuksorn W; Miners JO
    Pharmacogenet Genomics; 2006 May; 16(5):321-9. PubMed ID: 16609363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab-induced hyperbilirubinemia in Japanese patients with rheumatoid arthritis: its association with UDP glucuronosyltransferase 1A1 gene polymorphisms.
    Mori S; Terada K; Ueki Y
    Mod Rheumatol; 2012 Aug; 22(4):515-23. PubMed ID: 21993917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy.
    Lin KY; Liao SH; Liu WC; Cheng A; Lin SW; Chang SY; Tsai MS; Kuo CH; Wu MR; Wang HP; Hung CC; Chang SC
    PLoS One; 2015; 10(9):e0137660. PubMed ID: 26360703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between the UGT1A1*28 allele and hyperbilirubinemia in HIV-positive patients receiving atazanavir: a meta-analysis.
    Du P; Wang A; Ma Y; Li X
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30962262
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
    Eley T; Huang SP; Conradie F; Zorrilla CD; Josipovic D; Botes M; Osiyemi O; Hardy H; Bertz R; McGrath D
    AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1287-92. PubMed ID: 23782005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
    Johnson DH; Venuto C; Ritchie MD; Morse GD; Daar ES; McLaren PJ; Haas DW
    Pharmacogenet Genomics; 2014 Apr; 24(4):195-203. PubMed ID: 24557078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UGT1A1 sequence variants associated with risk of adult hyperbilirubinemia: a quantitative analysis.
    Chen Z; Su D; Ai L; Jiang X; Wu C; Xu Q; Wang X; Fan Z
    Gene; 2014 Nov; 552(1):32-8. PubMed ID: 25200497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A functional polymorphism in UGT1A1 related to hyperbilirubinemia is associated with a decreased risk for Crohn's disease.
    de Vries HS; Te Morsche RH; Jenniskens K; Peters WH; de Jong DJ
    J Crohns Colitis; 2012 Jun; 6(5):597-602. PubMed ID: 22398043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.
    Torti C; Lapadula G; Antinori A; Quirino T; Maserati R; Castelnuovo F; Maggiolo F; De Luca A; Paraninfo G; Antonucci F; Migliorino G; Lazzarin A; Di Perri G; Rizzardini G; Esposito R; Carosi G
    Infection; 2009 Jun; 37(3):244-9. PubMed ID: 19471856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detrimental effect of atazanavir plasma concentrations on total serum bilirubin levels in the presence of UGT1A1 polymorphisms.
    Cicconi P; Bini T; Barassi A; Casana M; Turri O; Pateri F; Marchetti GC; Biondi ML; d'Eril GM; d'Arminio Manforte A
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):e96-7. PubMed ID: 21317582
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.